Should You Buy Neil Woodford’s Patient Capital Trust?

This new fund could sit well beside a FTSE 100 (INDEXFTSE:UKX) tracker.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford’s new Patient Capital Trust is now open for subscription. The credentials and past success of Mr Woodford, and the innovative nature of the new fund, should make it highly popular with investors. But is it right for you?

10% p.a.

The fund’s objective is certainly attractive. Mr Woodford will target returns of 10% per annum in the long term. The clue is in the name: this is a fund for patient investors. But this fund is very different from Mr Woodford’s Equity Income Fund — or any other equity income fund, which typically invests in boring large-cap companies paying reliable dividends but with modest growth potential.

In contrast, Patient Capital will focus on small, emerging growth companies. Its target portfolio is:

  • 50% in ‘early-stage’ companies;
  • 25% in ‘early growth’ companies;
  • 25% in mid/large caps.

‘Early-stage’ companies might be quoted or unquoted and “are normally pre-revenue and pre-profit”. This is venture capital in all but name. ‘Early-growth’ companies are likely to be already quoted, and will have started to commercialise their inventions. They are less at risk of failure, whilst still offering fast growth prospects. The quarter of the fund devoted to mid and large caps will provide ballast and income.

What, no fees?

There’s another innovation from Mr Woodford: Patient Capital will not change an annual management fee, except for ongoing costs expected to be around 0.35% p.a. Instead, the manager will be remunerated by a performance fee only payable when the cumulative return of the fund exceeds 10% p.a. — then the manager will cream off 15% of the excess over 10% p.a.

Traditionally, performance fees have smacked of greed, but combined with the absence of a recurring fee it is a remarkable sign of confidence, aligning the manager’s interests with those of investors. It suggests Mr Woodford hopes to exceed the 10% target.

Obviously, this kind of investment is much higher risk than large quoted companies, but Mr Woodford is an experienced investor in early growth companies. For many investors, I think this could be an interesting low-cost fund to hold alongside a more traditional FTSE 100 tracker, which, by definition, is wholly comprised of large caps.

There is much to fault in the FTSE 100 index: it has taken longer than most to recover its pre-financial crash highs, bogged down by over-exposure to oil, miners and banks. But it’s an easy way for most investors to obtain a pure play on the market, and has returned a decent 9.8% and 9.2% p.a. over the past 3 and 5 years respectively.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony Reading has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »